openPR Logo
Press release

Nonerosive Reflux Disease Treatment Market: Outlook, Opportunity and Demand Analysis , Forecast 2018 to 2026

09-04-2018 10:55 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Fact.MR

/ PR Agency: Fact.MR
Nonerosive Reflux Disease Treatment Market: Outlook,

Patients with classical symptoms of gastroesophageal reflux disease (GERD) with normal esophageal mucosa (i.e. without inflammation) are generally identified to have Nonerosive reflux disease (NERD). The patients with nonerosive reflux disease have no common symptoms. Nonerosive reflux disease patient are one who have normal esophagus during endoscopy but GERD like symptoms. 50 to 70% patients with GERD and more than 49% patients with heartburn tend to have nonerosive reflux disease. Proton pump inhibitors (PPI) are therapeutically most efficient drugs in nonerosive reflux disease treatment though complete symptom control is low. H2 – blockers have low success rate in nonerosive reflux treatment but are having high usage. Reduced success rate of proton pump inhibitors in patients with GERD and heartburn is attributed to co-existing nonerosive reflux disease. Success of antireflux surgery in nonerosive reflux disease treatment is low when compared to erosive reflux disease. Antacids, Proton pump inhibitors and H2 – blockers are used in nonerosive reflux disease treatment and in case of chronic cases antireflux surgery is done.

Request Brochure of this Report at https://www.factmr.com/connectus/sample?flag=B&rep_id=1098
50 to 70% patients with GERD and 49% patients with heartburn tend to have nonerosive reflux disease, hence increasing prevalence of GERD and heartburn attributing to growth of nonerosive reflux disease treatment market. Development of GERD, Heartburn and nonerosive reflux disease is correlating to increasing prevalence of obesity and other dietary factors which are driving nonerosive reflux disease treatment market. Consequential impact on health related quality of life along with work related productivity is indicative of more chances to develop NERD which in term driving nonerosive reflux disease treatment market. Various studies have concluded that patients with nonerosive reflux disease have 20 to 30% less chances of getting relief from acid-blocking drugs hence making it difficult to treat nonerosive reflux disease with PPI. Non-availability of efficient treatment acting as a restraint in nonerosive reflux disease treatment market growth.  Difficulty in diagnosis of nonerosive reflux disease further makes treatment difficult attributing to low nonerosive reflux disease market growth. Higher doses of proton pump inhibitor drugs are reported to develop adverse events further making nonerosive reflux disease treatment difficult. There is no treatment strategy established for nonerosive reflux disease treatment.

The global nonerosive reflux disease treatment market is classified on the basis of product type, distribution channel and region

Based on the drug type nonerosive reflux disease treatment market is segmented into following:

Proton pump inhibitors
H2 – blockers
Antacids
Prokinetics
Based on the distribution channel nonerosive reflux disease treatment market is segmented into following:

Retail pharmacies
Hospital pharmacies
Online pharmacies
Various studies are going to develop strategy for treatment and diagnosis enhancing growth on nonerosive reflux disease market. Many studies are going on to distinguish nonerosive reflux disease patients from those with erosive esophagitis to make diagnosis and nonerosive reflux disease treatment efficient. Rising clinical studies in nonerosive reflux disease treatment are expected to drive market growth over forecast period. Advanced drug molecule development in proton pump inhibitor class is expected to improve PPI result in nonerosive reflux disease treatment. By drug type proton pump inhibitors segment is most preferred for nonerosive reflux disease treatment. By distribution channel retail pharmacies segment is expected to dominate due high preference. Increased studies to evaluate nonerosive reflux disease diagnosis and treatment is further attributed to drive nonerosive reflux disease treatment market.

On the basis of geography, global nonerosive reflux disease treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Region wise North America is most lucrative market due increased prevalence of gastroesophageal reflux disease (GERD) and heartburn. Health related lifestyle correlating to obesity in North America is responsible for increasing nonerosive reflux disease treatment market and is only expected to grow. Nonerosive reflux disease is most common in patients with GERD and prevalence of gastroesophageal reflux disease (GERD) in North America (20%), Europe (9-17%) Asia Pacific (2-5%) once a week which is further responsible for nonerosive reflux disease treatment.

Request TOC of this Report at https://www.factmr.com/connectus/sample?flag=T&rep_id=1098
Key major players in the nonerosive reflux disease treatment market are: AstraZeneca plc, Eisai Co, GlaxoSmithKline PLC; Takeda Pharmaceutical Co., Ltd, Johnson & Johnson, Daewoong Pharmaceutical Co., Ltd.; Ironwood Pharmaceuticals, Inc.; SRS Pharmaceuticals Pvt. Ltd.; and SFJ Pharmaceuticals Group

The report covers exhaustive analysis on:

Nonerosive reflux disease treatment Market Segments
Nonerosive reflux disease treatment Market Dynamics
Historical Actual Market Size, 2013 - 2017
Nonerosive reflux disease treatment Market Size & Forecast 2018 to 2024
Nonerosive reflux disease treatment Agents Current Trends/Issues/Challenges
Competition & Companies involved
Nonerosive reflux disease treatment Market Drivers and Restraints
Regional analysis includes

North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size recent industry trends
Key Competition landscape
Strategies for key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance
Report Analysis at https://www.factmr.com/report/1098/nonerosive-reflux-disease-treatment-market

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
FactMR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: www.factmr.com/
Follow Us on Linkedin: www.linkedin.com/company/factmr/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nonerosive Reflux Disease Treatment Market: Outlook, Opportunity and Demand Analysis , Forecast 2018 to 2026 here

News-ID: 1218261 • Views:

More Releases from Fact.MR

Ice Skating Equipment Market worth is poised to reach US$ 1478 Billion in 2033
03-28-2024 | Sports
Fact.MR
Ice Skating Equipment Market worth is poised to reach US$ 1478 Billion in 2033
The global ice skating equipment market garnered a market value of US$ 6.87 Billion in 2022 and is expected to accumulate a market value of US$ 16.26 Billion by registering a CAGR of 9% in the forecast period 2023-2033. Ice skating is a popular activity observed in numerous snow-clad regions around the world, serving various purposes including exercise, leisure, and excitement. This recreational pursuit can occur in specially prepared ice arenas
Global Barcode Software Market is predicted to be valued at US$ 1.4 Billion by 2032
Global Barcode Software Market is predicted to be valued at US$ 1.4 Billion by 2 …
The barcode software market is predicted to grow at a moderate CAGR of 6.3% over the forecast period of 2022 to 2032. The barcode software market is estimated to achieve a net worth of about US$ 1.4 Billion in the year 2032, improving from US$ 694.9 Million recorded in 2021. For more insights into the Market, Get A Sample of this Report! https://www.factmr.com/connectus/sample?flag=S&rep_id=7368 The barcode software market emerges as a crucial enabler of
Hardware Acceleration is forecasted to accelerate at a commendable CAGR of 51% from 2023 to 2033
Hardware Acceleration is forecasted to accelerate at a commendable CAGR of 51% f …
The global hardware acceleration market stands at US$ 2.87 billion in 2023. Worldwide demand for hardware acceleration technology is projected to skyrocket at a CAGR of 51% and reach a market value of US$ 177 billion by 2033. Hardware acceleration refers to the use of specialized hardware components to perform specific tasks more efficiently than general-purpose processors. This technology has gained significant traction across various industries due to its ability to
03-28-2024 | Food & Beverage
Fact.MR
Marine Collagen Ingredients Market value is projected to reach US$ 2,320.6 milli …
According to Fact.MR analysis, the marine collagen ingredients market is poised for steady growth in the coming years. The market's overall value is anticipated to exceed US$ 2,320.6 million by the year 2033, a significant increase from US$ 1,076.8 million recorded in 2023. Projections indicate a robust compound annual growth rate (CAGR) of 8.0% during the assessment period spanning from 2023 to 2033. Get Free Sample Copy of This Report: https://www.factmr.com/connectus/sample?flag=S&rep_id=8704 In recent

All 5 Releases


More Releases for Nonerosive

08-18-2021 | Health & Medicine
Fact.MR
Nonerosive Reflux Disease Treatment Market 2031 Report Enlightening Development …
The research report presents a market assessment of the Nonerosive Reflux Disease Treatment market and contains thoughtful insights, facts, and historical data and statistically supported and industry-validated market data It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application and industry 250 page market research report by Fact.MR, ( leading business and competitive intelligence provider),
Nonerosive Reflux Disease Treatment Market Information, Figures and Analytical I …
Patients with classical symptoms of gastroesophageal reflux disease (GERD) with normal esophageal mucosa (i.e. without inflammation) are generally identified to have Nonerosive reflux disease (NERD). The patients with nonerosive reflux disease have no common symptoms. Nonerosive reflux disease patient are one who have normal esophagus during endoscopy but GERD like symptoms. 50 to 70% patients with GERD and more than 49% patients with heartburn tend to have nonerosive reflux disease.
Nonerosive Reflux Disease Treatment Market Shares, Strategies and Forecast World …
Patients with classical symptoms of gastroesophageal reflux disease (GERD) with normal esophageal mucosa (i.e. without inflammation) are generally identified to have Nonerosive reflux disease (NERD). The patients with nonerosive reflux disease have no common symptoms. Nonerosive reflux disease patient are one who have normal esophagus during endoscopy but GERD like symptoms. 50 to 70% patients with GERD and more than 49% patients with heartburn tend to have nonerosive reflux disease.
Emerging Opportunities in Nonerosive Reflux Disease Treatment Market with Curren …
Patients with classical symptoms of gastroesophageal reflux disease (GERD) with normal esophageal mucosa (i.e. without inflammation) are generally identified to have Nonerosive reflux disease (NERD). The patients with nonerosive reflux disease have no common symptoms. Nonerosive reflux disease patient are one who have normal esophagus during endoscopy but GERD like symptoms. 50 to 70% patients with GERD and more than 49% patients with heartburn tend to have nonerosive reflux disease.
Nonerosive Reflux Disease Treatment Market to Reap Excessive Revenues by 2018 to …
Patients with classical symptoms of gastroesophageal reflux disease (GERD) with normal esophageal mucosa (i.e. without inflammation) are generally identified to have Nonerosive reflux disease (NERD). The patients with nonerosive reflux disease have no common symptoms. Nonerosive reflux disease patient are one who have normal esophagus during endoscopy but GERD like symptoms. 50 to 70% patients with GERD and more than 49% patients with heartburn tend to have nonerosive reflux disease.
07-25-2018 | Health & Medicine
Fact.MR
Nonerosive Reflux Disease Treatment Market Segments, Dynamics, Treatment Agents …
FACT.MR has been actively involved in offering comprehensive research data concerning various topics which are associated to industrial reference and investor utility. This particular research report titled “Nonerosive Reflux Disease Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2026” has been added to the wide online database of FACT.MR which discusses the present as well as future market scenario. Readers can access knowledge related to